专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

US20100099667A1 BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE 失效
标题翻译：桥联杂环化合物及其使用方法
公开(公告)号：US20100099667A1
公开(公告)日：2010-04-22
申请号：US12410425
申请日：2009-03-24
申请人： David T. Hung , Andrew Asher Protter , Sarjavit Chakravarty , Rajendra Parasmal Jain
发明人： David T. Hung , Andrew Asher Protter , Sarjavit Chakravarty , Rajendra Parasmal Jain
IPC分类号： A61K31/541 , C07D471/08 , C07D279/12 , C07D413/14 , A61K31/439 , A61K31/5377 , A61P25/18 , A61P25/28
CPC分类号： C07D451/00 , C07D471/08 , C07D471/18
摘要： This disclosure relates to new compounds that may be used to modulate a histamine receptor in an individual. Novel compounds are described, including new bridged heterocyclic [4,3-b]indole compounds. Pharmaceutical compositions are also provided. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.
摘要翻译：本公开涉及可用于调节个体中组胺受体的新化合物。描述了新的化合物，包括新的桥连杂环[4,3-b]吲哚化合物。还提供药物组合物。还提供了包含化合物的药物组合物，以及在多种治疗应用中使用化合物的方法，包括治疗认知障碍，精神病性障碍，神经递质介导的病症和/或神经元病症。

12. 发明授权

US07531511B2 Method for inducing angiogenesis or vascular perfusion in the myocardium comprising administering FGF-2 有权
标题翻译：用于诱导心肌中血管生成或血管灌注的方法，包括给予FGF-2
公开(公告)号：US07531511B2
公开(公告)日：2009-05-12
申请号：US11220027
申请日：2005-09-06
申请人： David T. Hung , Brian H. Annex , Kevin P. Landolfo , W. Michael Kavanaugh
发明人： David T. Hung , Brian H. Annex , Kevin P. Landolfo , W. Michael Kavanaugh
IPC分类号： A61K38/00 , C07K14/00
CPC分类号： A61K38/1858 , A61K38/1825 , A61K38/1866
摘要： The present invention has multiple aspects. In one aspect, the present invention is directed to a unit dose pharmaceutical composition comprising from about 5 ng/dose to less than 135,000 ng of an angiogenic agent, typically from 5 ng to 67,500 ng. Preferably, the angiogenic agent is FGF, more preferably it is basic FGF (FGF-2). In its second aspect, the present invention is directed to a method for inducing angiogenesis, or increasing myocardial perfusion or vascular density in a patient's heart, comprising administering directly into the myocardium in an area in need, as a single injection or a series of injections, a unit dose of an angiogenic agent. It is also within the scope of the present invention that a plurality of unit dose compositions be administered directly into the myocardium at a plurality of sites in need of angiogenesis. In another aspect, the present invention is directed to a method for treating a patient for coronary artery disease, comprising administering directly into the myocardium in an area of need of angiogenesis in said patient, a unit dose (i.e., from about 5 ng to less than 135,000 ng) of an angiogenic agent. In yet another aspect, the present invention is directed to a method for treating a patient for a myocardial infarction, comprising administering directly into the myocardium in an area in need of angiogenesis in said patient, a unit dose (i.e., from about 5 ng to less than 135,000 ng) of an angiogenic agent.
摘要翻译：本发明具有多个方面。一方面，本发明涉及包含约5ng /剂量至小于135,000ng血管生成剂（通常为5ng至67,500ng）的单位剂量药物组合物。优选地，血管生成剂是FGF，更优选是碱性FGF（FGF-2）。在其第二方面，本发明涉及用于诱导血管发生或增加患者心脏中的心肌灌注或血管密度的方法，包括在需要的区域中直接施用于心肌，作为单次注射或一系列注射，血管生成剂的单位剂量。在本发明的范围内，多个单位剂量组合物可以在需要血管生成的多个部位直接施用于心肌。另一方面，本发明涉及一种治疗患者冠状动脉疾病的方法，其包括在所述患者中需要血管生成的区域中直接对心肌施用单位剂量（即约5ng至少约5ng至超过135,000ng）血管生成剂。另一方面，本发明涉及用于治疗患者心肌梗塞的方法，包括在所述患者中需要血管生成的区域中直接施用心肌，单位剂量（即约5ng至小于135,000ng）血管生成剂。

13. 发明授权

US5902582A Use of TFPI inhibitor for treatment of cancer 失效
标题翻译：使用TFPI抑制剂治疗癌症
公开(公告)号：US5902582A
公开(公告)日：1999-05-11
申请号：US699897
申请日：1996-08-15
申请人： David T. Hung
发明人： David T. Hung
IPC分类号： A61K38/00 , A61K38/19 , A61K38/20 , A61K38/57 , C07K14/81 , C07K16/38
CPC分类号： A61K38/191 , A61K38/2006 , A61K38/204 , A61K38/57 , C07K14/8114 , C07K16/38
摘要： The invention provides for the inhibition of the activity of TFPI to prevent TFPI from countering the procoagulant activities associated with many tumors. Inhibition of TFPI activity by the method of the invention facilitates the propensity toward thrombosis in malignancies and therefore promotes tumor cell death. The method of the invention also includes, in addition to the administration of an inhibitor of TFPI, co-administration of an agent capable of inducing or augmenting in the targeted tumor the release or induction of factors that initiate or enhance clotting, such as TF and Factors VIIa and Xa.
摘要翻译：本发明提供抑制TFPI预防TFPI抵抗与许多肿瘤相关的促凝血活性的活性。通过本发明的方法抑制TFPI活性有助于恶性肿瘤中血栓形成的倾向，从而促进肿瘤细胞死亡。除了施用TFPI抑制剂之外，本发明的方法还包括：能够诱导或增强靶向肿瘤的药剂的共同给药，释放或诱导引发或增强凝血的因子，例如TF和因素VIIa和Xa。

14. 发明授权

US08178493B2 Method for inducing angiogenesis in a heart of a patient 有权
标题翻译：在患者心脏中诱导血管发生的方法
公开(公告)号：US08178493B2
公开(公告)日：2012-05-15
申请号：US12419038
申请日：2009-04-06
申请人： David T. Hung , Brian H. Annex , Kevin P. Landolfo , W. Michael Kavanaugh
发明人： David T. Hung , Brian H. Annex , Kevin P. Landolfo , W. Michael Kavanaugh
IPC分类号： C07K14/50 , C07K14/515 , A61K38/00
CPC分类号： A61K38/1858 , A61K38/1825 , A61K38/1866
摘要： The present invention has multiple aspects. In one aspect, the present invention is directed to a unit dose pharmaceutical composition comprising from about 5 ng/dose to less than 135,000 ng of an angiogenic agent, typically from 5 ng to 67,500 ng. Preferably, the angiogenic agent is FGF, more preferably it is basic FGF (FGF-2). In its second aspect, the present invention is directed to a method for inducing angiogenesis, or increasing myocardial perfusion or vascular density in a patient's heart, comprising administering directly into the myocardium in an area in need, as a single injection or a series of injections, a unit dose of an angiogenic agent. It is also within the scope of the present invention that a plurality of unit dose compositions be administered directly into the myocardium at a plurality of sites in need of angiogenesis. In another aspect, the present invention is directed to a method for treating a patient for coronary artery disease, comprising administering directly into the myocardium in an area of need of angiogenesis in said patient, a unit dose (i.e., from about 5 ng to less than 135,000 ng) of an angiogenic agent. In yet another aspect, the present invention is directed to a method for treating a patient for a myocardial infarction, comprising administering directly into the myocardium in an area in need of angiogenesis in said patient, a unit dose (i.e., from about 5 ng to less than 135,000 ng) of an angiogenic agent.
摘要翻译：本发明具有多个方面。一方面，本发明涉及包含约5ng /剂量至小于135,000ng血管生成剂（通常为5ng至67,500ng）的单位剂量药物组合物。优选地，血管生成剂是FGF，更优选是碱性FGF（FGF-2）。在其第二方面，本发明涉及用于诱导血管发生或增加患者心脏中的心肌灌注或血管密度的方法，包括在需要的区域中直接施用于心肌，作为单次注射或一系列注射，血管生成剂的单位剂量。在本发明的范围内，多个单位剂量组合物可以在需要血管生成的多个部位直接施用于心肌。另一方面，本发明涉及一种治疗患者冠状动脉疾病的方法，其包括在所述患者中需要血管生成的区域中直接对心肌施用单位剂量（即约5ng至少约5ng至超过135,000ng）血管生成剂。另一方面，本发明涉及用于治疗患者心肌梗塞的方法，包括在所述患者中需要血管生成的区域中直接施用心肌，单位剂量（即约5ng至小于135,000ng）血管生成剂。

15. 发明申请

US20090221504A1 DOSE OF AN ANGIOGENIC FACTOR AND METHOD OF ADMINISTERING TO IMPROVE MYOCARDIAL BLOOD FLOW 有权
标题翻译：抗血小板因子的剂量和施用方法以改善心肌血流量
公开(公告)号：US20090221504A1
公开(公告)日：2009-09-03
申请号：US12419038
申请日：2009-04-06
申请人： David T. Hung , Brian H. Annex , Kevin P. Landolfo , W. Michael Kavanaugh
发明人： David T. Hung , Brian H. Annex , Kevin P. Landolfo , W. Michael Kavanaugh
IPC分类号： A61K38/18 , A61P9/00
CPC分类号： A61K38/1858 , A61K38/1825 , A61K38/1866
摘要： The present invention has multiple aspects. In one aspect, the present invention is directed to a unit dose pharmaceutical composition comprising from about 5 ng/dose to less than 135,000 ng of an angiogenic agent, typically from 5 ng to 67,500 ng. Preferably, the angiogenic agent is FGF, more preferably it is basic FGF (FGF-2). In its second aspect, the present invention is directed to a method for inducing angiogenesis, or increasing myocardial perfusion or vascular density in a patient's heart, comprising administering directly into the myocardium in an area in need, as a single injection or a series of injections, a unit dose of an angiogenic agent. It is also within the scope of the present invention that a plurality of unit dose compositions be administered directly into the myocardium at a plurality of sites in need of angiogenesis. In another aspect, the present invention is directed to a method for treating a patient for coronary artery disease, comprising administering directly into the myocardium in an area of need of angiogenesis in said patient, a unit dose (i.e., from about 5 ng to less than 135,000 ng) of an angiogenic agent. In yet another aspect, the present invention is directed to a method for treating a patient for a myocardial infarction, comprising administering directly into the myocardium in an area in need of angiogenesis in said patient, a unit dose (i.e., from about 5 ng to less than 135,000 ng) of an angiogenic agent.
摘要翻译：本发明具有多个方面。一方面，本发明涉及包含约5ng /剂量至小于135,000ng血管生成剂（通常为5ng至67,500ng）的单位剂量药物组合物。优选地，血管生成剂是FGF，更优选是碱性FGF（FGF-2）。在其第二方面，本发明涉及用于诱导血管发生或增加患者心脏中的心肌灌注或血管密度的方法，包括在需要的区域中直接施用于心肌，作为单次注射或一系列注射，血管生成剂的单位剂量。在本发明的范围内，多个单位剂量组合物可以在需要血管生成的多个部位直接施用于心肌。另一方面，本发明涉及一种治疗患者冠状动脉疾病的方法，其包括在所述患者中需要血管生成的区域中直接对心肌施用单位剂量（即约5ng至少约5ng至超过135,000ng）血管生成剂。另一方面，本发明涉及用于治疗患者心肌梗塞的方法，包括在所述患者中需要血管生成的区域中直接施用心肌，单位剂量（即约5ng至小于135,000ng）血管生成剂。

16. 发明授权

US06638727B1 Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer 有权
标题翻译：识别治疗或监测无症状患者降低或治疗乳腺癌的方法
公开(公告)号：US06638727B1
公开(公告)日：2003-10-28
申请号：US09313463
申请日：1999-05-17
申请人： David T. Hung , Susan Love
发明人： David T. Hung , Susan Love
IPC分类号： G01N33574
CPC分类号： A61K31/4535 , A61K31/00 , A61K31/138 , A61K31/352 , A61K31/4196 , A61K31/437 , A61K31/566 , C12Q1/6886 , G01N33/5091 , G01N33/57415 , G01N2333/723 , A61K2300/00
摘要： The invention is to methods for identifying asymptomatic patients who have a likelihood of benefiting from administration of an estrogen activity modulator for risk reduction or therapeutic treatment of breast cancer, methods for reducing risk or therapeutically treating these asymptomatic patients, and methods for monitoring the treatments.
摘要翻译：本发明是用于鉴定有可能受益于雌激素活性调节剂用于降低或治疗乳腺癌的可能性的无症状患者的方法，用于降低风险或治疗这些无症状患者的方法以及用于监测治疗的方法。

17. 发明授权

US06610484B1 Identifying material from a breast duct 有权
标题翻译：从乳房管道识别材料
公开(公告)号：US06610484B1
公开(公告)日：2003-08-26
申请号：US09625399
申请日：2000-07-26
申请人： David T. Hung
发明人： David T. Hung
IPC分类号： C12Q300
CPC分类号： G01N33/57484 , A61B10/0041 , A61K31/00 , A61K31/138 , A61K31/352 , A61K31/4196 , A61K31/437 , A61K31/4535 , A61K31/566 , A61M3/0262 , A61M3/0279 , A61M2210/1007 , C12Q1/6806 , C12Q1/6886 , G01N33/57415 , G01N33/57492 , A61K2300/00
摘要： Methods and systems for identifying material from a breast duct using one or more markers that can be identified in ductal fluid retrieved from the breast are provided.
摘要翻译：提供了使用可从乳房检索的导管液中鉴定的一种或多种标记物从乳房导管识别材料的方法和系统。

18. 发明申请

US20120034644A1 IDENTIFYING MATERIAL FROM A BREAST DUCT 审中-公开
标题翻译：鉴定一种乳制品的材料
公开(公告)号：US20120034644A1
公开(公告)日：2012-02-09
申请号：US13210161
申请日：2011-08-15
申请人： David T. Hung
发明人： David T. Hung
IPC分类号： C12Q1/02
CPC分类号： G01N33/57484 , A61B10/0041 , A61K31/00 , A61K31/138 , A61K31/352 , A61K31/4196 , A61K31/437 , A61K31/4535 , A61K31/566 , A61M3/0262 , A61M3/0279 , A61M2210/1007 , C12Q1/6806 , C12Q1/6886 , G01N33/57415 , G01N33/57492 , A61K2300/00
摘要： Methods and systems for identifying material from a breast duct using one or more markers that can be identified in ductal fluid retrieved from the breast are provided.
摘要翻译：提供了使用可从乳房检索的导管液中鉴定的一种或多种标记物从乳房导管识别材料的方法和系统。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式